deltatrials
Completed PHASE1 INTERVENTIONAL 8-arm NCT01148849

Safety Study of MGAH22 in HER2-positive Carcinomas

A Phase 1, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available

Sponsor: Green Cross Corporation

Conditions Breast Cancer Gastric Cancer
Interventions margetuximab
Updated 15 times since 2017 Last updated: Feb 24, 2025 Started: Jul 31, 2010 Primary completion: Jun 14, 2022 Completion: Jun 14, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01148849, this PHASE1 trial focuses on Breast Cancer and Gastric Cancer and remains completed. Sponsored by Green Cross Corporation, it has been updated 15 times since 2010, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~May 2019 · 8 months · monthly snapshot~May 2019 – ~Mar 2020 · 10 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2022 · 14 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Mar 2025 — Sep 2025 [monthly]

    Completed PHASE1

  3. Sep 2024 — Mar 2025 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 10 earlier versions

  1. Sep 2022 — Nov 2022 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  6. May 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  7. Sep 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE1

  8. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1

  9. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  10. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Green Cross Corporation
  • MacroGenics
  • National Cancer Institute (NCI)
Data source: MacroGenics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations